Page last updated: 2024-11-04

methyl salicylate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Methyl salicylate, also known as oil of wintergreen, is a naturally occurring organic compound found in various plants. It is a colorless liquid with a strong, sweet, minty odor. Methyl salicylate is synthesized by the reaction of methanol with salicylic acid in the presence of an acid catalyst. This compound is primarily used as a flavoring agent and fragrance in pharmaceuticals, cosmetics, and food products. It is also a popular ingredient in topical analgesics for its anti-inflammatory and pain-relieving properties. Methyl salicylate is studied extensively for its potential therapeutic applications, including its anti-cancer and anti-bacterial effects. The compound acts as a COX-2 inhibitor, reducing the production of prostaglandins, which are involved in inflammation and pain signaling. Its importance lies in its versatility, offering a range of benefits in various industries, from pharmaceuticals to flavoring and fragrance.'

methyl salicylate: used in over-the-counter liniments, ointments, lotions for relief of musculoskeletal aches and pains; has hemolytic effect on human & sheep erythrocytes; RN given refers to parent cpd; structure in Merck Index, 9th ed, #5990 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

methyl salicylate : A benzoate ester that is the methyl ester of salicylic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
Betula lentaspecies[no description available]BetulaceaeA plant family of the order Fagales, subclass Hamamelidae, class Magnoliopsida. They have simple, serrate, alternate leaves. Male flowers are borne in long, pendulous catkins; the female in shorter, pendulous or erect catkins. The fruit is usually a small nut or a short-winged samara.[MeSH]
Betula lentaspecies[no description available]BetulaceaeA plant family of the order Fagales, subclass Hamamelidae, class Magnoliopsida. They have simple, serrate, alternate leaves. Male flowers are borne in long, pendulous catkins; the female in shorter, pendulous or erect catkins. The fruit is usually a small nut or a short-winged samara.[MeSH]
BetulagenusA plant genus of the family BETULACEAE. The tree has smooth, resinous, varicolored or white bark, marked by horizontal pores (lenticels), which usually peels horizontally in thin sheets.[MeSH]BetulaceaeA plant family of the order Fagales, subclass Hamamelidae, class Magnoliopsida. They have simple, serrate, alternate leaves. Male flowers are borne in long, pendulous catkins; the female in shorter, pendulous or erect catkins. The fruit is usually a small nut or a short-winged samara.[MeSH]

Cross-References

ID SourceID
PubMed CID4133
CHEMBL ID108545
CHEBI ID31832
SCHEMBL ID5312
MeSH IDM0102760

Synonyms (215)

Synonym
BIDD:ER0323
AB01275470-01
gtpl2431
betula
salicylic acid, methyl ester
betula lenta
metylester kyseliny salicylove
119-36-8
analgit
nsc-8204
exagien
wln: qr bvo1
flucarmit
o-hydroxybenzoic acid, methyl ester
methyl salicylate
wintergruenoel
gaultheriaoel
methyl o-hydroxybenzoate
nsc8204
methyl 2-hydroxybenzoate
2-hydroxybenzoic acid, methyl ester
2-(methoxycarbonyl)phenol
ENAMINE_001611
fema no. 2154
fema no. 2745
epa pesticide chemical code 076601
einecs 204-317-7
metylester kyseliny salicylove [czech]
nsc 8204
fema number 2745
caswell no. 577
ai3-00090
brn 0971516
2-hydroxybenzoic acid methyl ester
ccris 6259
methyl salicylate (natural)
theragesic
hsdb 1935
panalgesic
2-carbomethoxyphenol
methylester kyseliny salicylove [czech]
methyl salicylate [jan]
benzoic acid, 2-hydroxy-, methyl ester
NCGC00091106-01
inchi=1/c8h8o3/c1-11-8(10)6-4-2-3-5-7(6)9/h2-5,9h,1h
methyl salicylate, >=98%, fcc, fg
methyl salicylate, bioxtra
methyl salicylate, reagentplus(r), >=99% (gc)
methyl salicylate (jp17/nf)
D01087
methyl salicylate (tn)
NCGC00091106-02
STK397388
1-o-methylsalicylate
salicylate methyl ester
methylsalicylate
AC-11584
HMS2089H12
HMS1398J05
fema no. 3113
chebi:31832 ,
flavor,wintergreen
CHEMBL108545
methyl salicylate,synthetic
8024-54-2
salicylic acid methyl ester
AKOS000118977
A804265
NCGC00091106-03
NCGC00091106-04
68917-75-9
NCGC00259093-01
tox21_201543
tox21_300137
NCGC00254104-01
BBL010504
2-hydroxy-benzoic acid methyl ester
68917-50-0
wintergreen
dtxsid5025659 ,
tox21_111081
dtxcid805659
cas-119-36-8
S3756
anthrapole nd
4-10-00-00143 (beilstein handbook reference)
lav5u5022y ,
methylester kyseliny salicylove
ec 204-317-7
methyl salicylate [jan:nf]
unii-lav5u5022y
predalure
ben gay
FT-0622968
FT-0612582
benzoic acid, hydroxy-, methyl ester
90045-28-6
o-hydroxybenzoic acid methyl ester
salonpas component methyl salicylate
methyl salicylate [who-dd]
methyl salicylate [vandf]
methyl salicylate [ep impurity]
methyl salicylate [hsdb]
methyl salicylate [mi]
wintergreen [vandf]
methyl salicylate [mart.]
methyl salicylate component of salonpas
methyl salicylate [fcc]
methyl salicylate [fhfi]
methyl salicylate [usp-rs]
methyl salicylate [ii]
methyl salicylate,synthetic [vandf]
methyl salicylate [orange book]
methyl salicylate [ep monograph]
methyl salicylate [inci]
302912-49-8
methyl-d3 salicylate-od
salicylic-acid methyl ester
methyl-2-hydroxybenzoate
SCHEMBL5312
NCGC00091106-05
TS-02010
1219802-12-6
Q-100939
salonpas (salt/mix)
theragesic (salt/mix)
methyl ester of 2-hydroxy-benzoic acid
mfcd00002214
HY-Y0189
FT-0698844
methyl salicylate, analytical standard
methyl salicylate, tested according to ph.eur.
F0001-0306
sr-05000001473
SR-05000001473-1
methyl salicylate, united states pharmacopeia (usp) reference standard
methyl salicylate, saj first grade, >=98.0%
D70335
methyl salicylate, pharmaceutical secondary standard; certified reference material
methyl salicylate, natural, 98%, fcc, fg
methyl salicylate, vetec(tm) reagent grade, 99%
methyl salicylate, 98%
methyl salicylate, puriss., 99.0-100.5%
fema 2745
methyl ester 2-hydroxy-benzoic acid
methyl salicylate, 8ci
methyl2-hydroxybenzoate
135952-76-0
Z19703590
DB09543
CS-B1799
FT-0695782
Q407669
methyl salicylate
methyl salicylate,(s)
methyl salicylate 100 microg/ml in acetonitrile
2,4-cyclohexadien-1-one,6-(hydroxymethoxymethylene)-(9ci)
HMS3885C04
methyl-salicylate
BCP29151
CCG-266225
SY008800
EN300-15491
methyl 2-hydroxybenzoate--d4
9041-28-5
methylsalicylate-d3
germa linimento ubre plus (roll-on)
foot worksarthritis achy foot and muscle
methyl salicylate (mart.)
germa ubre mastitis
la flecha japonesa
methyl salicylate 2%
methyl salicylate 10%
neuro max pain and muscle relief gel
hysan hua tuo medicated
veneno de abejaaceite de vibora brand
mascura la vaca plus
herb street sore muscle relief
hyundai moolpas f
krona wart remover
xceptor pain
east coast joint relief
methyl salicylate (ep monograph)
ted s pain
kofal fuerte
bumooly-s
methyl salicylate (usp-rs)
coats aloe analgesic
kofal
dermaline 3 in 1 roll on
teds topical pain cream
kofal original
natralia cramp relief
germa manteca ubre plus (tin)
milagroso
ubredol
balsamo de ubremascura
germa manteca ubre plus (red)
methyl salicylate, aloe
methyl salicylate (ii)
koong yick hung fa
aspi-rubpain reliever
releaf arthritis balm
xceptor cbd painmenthol
methyl salicylate (ep impurity)
germa linimento ubre plus
sunset pain relief-heating relief
flexsport roll on
flexitol foot and knee pain relief
germa manteca ubre plus (yellow)
balsamo de vaca mascura
zenol cool
ling nam hung far
abejas y viboras roll on
oils,wintergreen

Research Excerpts

Overview

Methyl salicylate is a volatile compound, the synthesis of which takes place via the salicylic acid pathway in plants. It is an important inter- and intra-plant signaling molecule, but is deemed undesirable by humans when it accumulates to high levels in ripe fruits. Methyl salICylate (MS) is a non-steroidal topical anti-inflammatory drug (NSAID)

ExcerptReferenceRelevance
"Methyl salicylate is a volatile compound, the synthesis of which takes place via the salicylic acid pathway in plants. "( The role of methyl salicylate in plant growth under stress conditions.
Gondor, OK; Janda, T; Pál, M; Szalai, G, 2022
)
2.54
"Methyl salicylate (MeSal) is an organic compound present in plants during stress events and is therefore a key marker for early plant disease detection. "( New trends in methyl salicylate sensing and their implications in agriculture.
Ashrafi, AM; Bytešníková, Z; Cané, C; Richtera, L; Vallejos, S, 2023
)
2.71
"Methyl salicylate is an important inter- and intra-plant signaling molecule, but is deemed undesirable by humans when it accumulates to high levels in ripe fruits. "( Structural variation underlies functional diversity at methyl salicylate loci in tomato.
Pereira, L; Sapkota, M; Tieman, D; Topcu, Y; van der Knaap, E; Wang, Y; Zhang, L, 2023
)
2.6
"Methyl salicylate (MS) is a non-steroidal topical anti-inflammatory drug (NSAID)."( Chitosan-based films containing nanoemulsions of methyl salicylate: Formulation development, physical-chemical and in vitro drug release characterization.
Barradas, TN; de Holanda E Silva, KG; Picciani, PHS; Reynaud, F; Silva, TND, 2020
)
1.53
"Methyl salicylate (MeSA) is a volatile biological compound synthesized from salicylic acid (SA) and is a plant hormone that helps defend against pests and pathogens. "( Seed treatment and foliar application of methyl salicylate (MeSA) as a defense mechanism in rice plants against the pathogenic bacterium, Xanthomonas oryzae pv. oryzae.
Kalaivani, K; Maruthi-Kalaiselvi, M; Senthil-Nathan, S, 2021
)
2.33
"Methyl salicylate (MeSA) is a plant metabolite that induces plant defence resistance and an odorous volatile compound presenting green nuances. "( Methyl salicylate, a grape and wine chemical marker and sensory contributor in wines elaborated from grapes affected or not by cryptogamic diseases.
Bruez, E; Cholet, C; Darriet, P; Delière, L; Geny-Denis, L; Marchal, A; Poitou, X; Pons, A; Redon, P, 2021
)
3.51
"Methyl salicylate (MeSA) is a long-distance signal transduction chemical that plays an important role in plant responses to abiotic stress and herbivore and pathogen attacks. "( Methyl salicylate differently affects benzenoid and terpenoid volatile emissions in Betula pendula.
Jiang, Y; Kaurilind, E; Liu, B; Niinemets, Ü, 2018
)
3.37
"Methyl salicylate (MeSA) is a green leaf volatile (GLV) compound that is emitted in significant amounts by plants, especially when they are under stress conditions. "( Molecular modeling of the green leaf volatile methyl salicylate on atmospheric air/water interfaces.
Ehrenhauser, FS; Hansel, AK; Hung, FR; Liyana-Arachchi, TP; Stevens, C; Valsaraj, KT, 2013
)
2.09
"Methyl salicylate (MeSa) is a stress hormone released by plants under attack by pathogens or herbivores . "( Neuropeptide receptors NPR-1 and NPR-2 regulate Caenorhabditis elegans avoidance response to the plant stress hormone methyl salicylate.
Luo, J; Ma, L; Tan, Z; Xu, Z; Zhang, Z, 2015
)
2.07
"Methyl salicylate (MeSA) is a volatile organic compound synthesized from salicylic acid (SA) a plant hormone that helps to fight against plant disease. "( Effect of methyl salicylate (MeSA), an elicitor on growth, physiology and pathology of resistant and susceptible rice varieties.
Kalaiselvi, MM; Kalaivani, K; Senthil-Nathan, S, 2016
)
2.28
"Methyl salicylate (MeSA) is a volatile plant secondary metabolite that is an important contributor to taste and scent of many fruits and flowers. "( Functional analysis of a tomato salicylic acid methyl transferase and its role in synthesis of the flavor volatile methyl salicylate.
Jones, JB; Klee, HJ; Rushing, S; Schmelz, E; Taylor, MG; Tieman, D; Zeigler, M, 2010
)
2.01
"Methyl salicylate (MeSA) is a common herbivore-induced plant volatile that, when applied to crops, has the potential to enhance natural enemy abundance and pest control. "( Effect of methyl salicylate-based lures on beneficial and pest arthropods in strawberry.
Lee, JC, 2010
)
2.21
"Methyl salicylate (MeSA) is a HIPV that is attractive to several key predators of two-spotted spider mite, Tetranychus urticae Koch (Acari: Tetranychidae), and hop aphid, Phorodon humuli (Schrank) (Homoptera: Aphididae)."( Evaluation of airborne methyl salicylate for improved conservation biological control of two-spotted spider mite and hop aphid in Oregon hop yards.
Gent, DH; James, DG; Lee, JC; Woods, JL, 2011
)
1.4
"Methyl salicylate is a compound currently used in the creation of many flavors. "( Natural abundance 2H-ERETIC-NMR authentication of the origin of methyl salicylate.
Akoka, S; George, G; Le Grand, F, 2005
)
2.01
"Methyl salicylate continues to be a relatively common source of pediatric exposures."( Are one or two dangerous? Methyl salicylate exposure in toddlers.
Davis, JE, 2007
)
1.36

Effects

Methyl salicylate has been identified as one of the most important volatile organic compounds released by plants during a biotic stress event such as fungal pathogen infection. It is used extensively for liquid- and vapor-permeation testing.

ExcerptReferenceRelevance
"Methyl salicylate (MeS) has a rich history as an inert physical simulant for the chemical warfare agents sulfur mustard and soman, where it is used extensively for liquid- and vapor-permeation testing. "( Methyl salicylate: a reactive chemical warfare agent surrogate to detect reaction with hypochlorite.
Owens, JR; Salter, WB; Wander, JD, 2011
)
3.25
"Methyl salicylate has been identified as one of the most important volatile organic compounds released by plants during a biotic stress event such as fungal pathogen infection."( Detection of methyl salicylate using bi-enzyme electrochemical sensor consisting salicylate hydroxylase and tyrosinase.
Bullock, H; Eiteman, MA; Fang, Y; Lee, SA; Ramasamy, RP; Sekar, N; Whitman, WB, 2016
)
1.52
"Methyl salicylate (MeS) has a rich history as an inert physical simulant for the chemical warfare agents sulfur mustard and soman, where it is used extensively for liquid- and vapor-permeation testing. "( Methyl salicylate: a reactive chemical warfare agent surrogate to detect reaction with hypochlorite.
Owens, JR; Salter, WB; Wander, JD, 2011
)
3.25
"Methyl salicylate (MS) has historically been the simulant of choice to assess HD exposure."( Use of methyl salicylate as a simulant to predict the percutaneous absorption of sulfur mustard.
Brooks, JD; Budsaba, K; Monteiro-Riviere, NA; Olajos, EJ; Riviere, JE; Salem, H; Smith, CE,
)
1.31

Actions

ExcerptReferenceRelevance
"Methyl salicylate displayed a lower toxicity (LC50  =  1.17 µl/l air, 24 h) but the fastest knockdown activity (KT95  =  16.8 min) at the sublethal concentration 0.5 µl/l air."( Fumigant Activity of 6 Selected Essential Oil Compounds and Combined Effect of Methyl Salicylate And Trans-Cinnamaldehyde Against Culex pipiens pallens.
Feng, JT; Jiang, ZL; Ma, WB; Zhang, X, 2014
)
1.35

Treatment

ExcerptReferenceRelevance
"Treatment with methyl salicylate antagonized the signaling pathway of wounding."( Characterization of cDNAs encoding two distinct miraculin-like proteins and stress-related modulation of the corresponding mRNAs in Citrus jambhiri lush.
Akimitsu, K; Gomi, K; Tsukuda, S; Yamamoto, H, 2006
)
0.67

Toxicity

ExcerptReferenceRelevance
"The adverse effect of topical methylsalicylate ointment on warfarin anticoagulation is studied in 11 patients."( Adverse effect of topical methylsalicylate ointment on warfarin anticoagulation: an unrecognized potential hazard.
Cheung, KL; Chow, WH; Tai, YT; Yip, AS, 1990
)
0.28
"High-dose, subcutaneous IT is efficacious and safe in patients with severe birch pollen rhinoconjunctivitis and asthma."( The safety and efficacy of subcutaneous birch pollen immunotherapy - a one-year, randomised, double-blind, placebo-controlled study.
Bødtger, U; Jacobi, HH; Malling, HJ; Poulsen, LK, 2002
)
0.31
" Nonalcoholic ingredients of this mouthwash are phenolic compounds (eucalyptol, menthol, and thymol), and large-volume mouthwash ingestion will produce exposure in the reported toxic range of these ingredients."( Fatal large-volume mouthwash ingestion in an adult: a review and the possible role of phenolic compound toxicity.
Dinovo, E; Hinds, RL; Renner, SW; Soo Hoo, GW,
)
0.13
" These compounds, in addition to alcohol, may account for the adverse effects associated with massive mouthwash ingestion."( Fatal large-volume mouthwash ingestion in an adult: a review and the possible role of phenolic compound toxicity.
Dinovo, E; Hinds, RL; Renner, SW; Soo Hoo, GW,
)
0.13
" Safety data, including adverse events, and secondary efficacy end points were also evaluated."( Efficacy and safety profile of a topical methyl salicylate and menthol patch in adult patients with mild to moderate muscle strain: a randomized, double-blind, parallel-group, placebo-controlled, multicenter study.
Furuta, K; Higashi, Y; Kiuchi, T, 2010
)
0.63
" STE is far less toxic in hepatocytes."( In vitro cytotoxicity of cyclodextrin-bonded birch bark extract.
Giesemann, T; Gründemann, C; Hertrampf, A; Huber, R; Jäger, S; Laszczyk, M, 2012
)
0.38
" However, these massage oils may be toxic when taken orally."( Salicylate toxicity from ingestion of traditional massage oil.
Muniandy, RK; Sinnathamby, V, 2012
)
0.38
"All patients tolerated the intralymphatic immunotherapy (ILIT) treatment well, and the injections did not elicit any severe adverse event."( Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Cardell, LO; Hylander, T; Latif, L; Petersson-Westin, U, 2013
)
0.39
"Sublingual immunotherapy (SLIT) is a potential efficacious and safe treatment option for patients with respiratory, IgE-mediated allergic diseases."( A randomized DBPC trial to determine the optimal effective and safe dose of a SLIT-birch pollen extract for the treatment of allergic rhinitis: results of a phase II study.
Boot, JD; Diamant, Z; Klimek, L; Kuna, P; Opstelten, DJ; Panzner, P; Pfaar, O; van Ree, R; van Twuijver, E, 2016
)
0.43
" All active dosages resulted in more adverse reactions than placebo, which were mainly mild and well-controlled."( A randomized DBPC trial to determine the optimal effective and safe dose of a SLIT-birch pollen extract for the treatment of allergic rhinitis: results of a phase II study.
Boot, JD; Diamant, Z; Klimek, L; Kuna, P; Opstelten, DJ; Panzner, P; Pfaar, O; van Ree, R; van Twuijver, E, 2016
)
0.43
" The results indicate that, within the studied dose range, SB 40,000 AUN/ml is the most optimal effective and safe dose (ClinicalTrials."( A randomized DBPC trial to determine the optimal effective and safe dose of a SLIT-birch pollen extract for the treatment of allergic rhinitis: results of a phase II study.
Boot, JD; Diamant, Z; Klimek, L; Kuna, P; Opstelten, DJ; Panzner, P; Pfaar, O; van Ree, R; van Twuijver, E, 2016
)
0.43
" Importantly, using in vivo imaging techniques we demonstrated that intranasally applied EcN do not permanently colonize nose, lung, and gut and this strain might therefore be a safe delivery vector against allergy in humans."( E. coli Nissle 1917 is a safe mucosal delivery vector for a birch-grass pollen chimera to prevent allergic poly-sensitization.
Daniel, C; Drinić, M; Heinl, S; Poiret, S; Sarate, PJ; Schabussova, I; Wiedermann, U; Zwicker, C, 2019
)
0.51
"Mild-to-moderate treatment-related adverse events were reported for 57."( Fast up-dosing with a birch allergoid is safe and well tolerated in allergic rhinitis patients with or without asthma.
Akboga, Y; Plückhahn, K; Rieker-Schwienbacher, J; Rosewich, M; Thieme, U; Zielen, S, 2019
)
0.51
" Safety determination was assessed by evaluating local and systemic adverse events."( Evaluation of safety and tolerability of a rush up-dosing allergen-specific immunotherapy with grass pollen, birch, hazel, and alder allergoid in children with allergic rhinoconjunctivitis, with or without asthma.
Barberi, S; Ciprandi, G; Licari, A; Marseglia, GL; Martelli, A; Tosca, MA; Traina, G, 2021
)
0.62
" Mild, local, treatment-emergent adverse events were noted throughout the course of treatment but resolved spontaneously."( Case Report: Safe and Effective Sublingual Birch Allergen Immunotherapy in Two HIV-Positive Patients.
Ilina, N; Latysheva, E; Latysheva, T; Nazarova, E, 2021
)
0.62
" Adverse events (AEs) occurred with similar frequency for Oleogel-S10 (81·7%) compared with control gel (80·7%)."( Efficacy and safety of Oleogel-S10 (birch triterpenes) for epidermolysis bullosa: results from the phase III randomized double-blind phase of the EASE study.
Bodemer, C; Bruckner, AL; Cunningham, T; Davis, C; Fernandez, MF; Kern, JS; Löwe, S; Murrell, DF; Schauer, F; Sprecher, E; Sumeray, M, 2023
)
0.91

Compound-Compound Interactions

ExcerptReferenceRelevance
"MeSA combined with 1-MCP treatment was a useful technique to maintain quality and alleviate gray mold in postharvest tomato fruit during storage."( Effect of methyl salicylate in combination with 1-methylcyclopropene on postharvest quality and decay caused by Botrytis cinerea in tomato fruit.
Cui, X; Dong, L; Li, F; Li, J; Meng, D; Min, D; Ren, C; Shu, P; Zhang, X, 2018
)
0.88

Bioavailability

ExcerptReferenceRelevance
" Differences in time courses of the responses which were not altered by experimentally varying rate of absorption and in components of the inflammatory response to the three irritants suggest that chemicals induce skin irritation by multiple mechanisms."( Mechanisms of chemically induced skin irritation. I. Studies of time course, dose response, and components of inflammation in the laboratory mouse.
Burkhalter, A; Maibach, HI; Patrick, E, 1985
)
0.27
"The total amount of salicylate recovered in the urine during two dosing intervals (24 hours) on each study day, relative to the applied dose, was used to calculate the bioavailability of each product."( Serum concentrations of salicylic acid following topically applied salicylate derivatives.
Bartle, WR; Bowles, SK; Lee, SN; Morra, P; Reeves, RA; Walker, SE, 1996
)
0.29
" Both the extent and rate of absorption changed after the first 24 hours."( Serum concentrations of salicylic acid following topically applied salicylate derivatives.
Bartle, WR; Bowles, SK; Lee, SN; Morra, P; Reeves, RA; Walker, SE, 1996
)
0.29
" Both the ASA conversion factor to yield the ASA equivalent dose and the treatment guideline assume 100% bioavailability of the salicylate."( Plasma salicylate from methyl salicylate cream compared to oil of wintergreen.
Casavant, MJ; Hadley, CM; Kelley, MT; Walson, PD; Wolowich, WR, 2003
)
0.63
" Although unable to determine the absolute dermal bioavailability of these compounds, there appears to be relatively low systemic exposure to these potentially toxic compounds, even when an unrealistically large number of patches are applied for an unusually long time."( Dermal absorption of camphor, menthol, and methyl salicylate in humans.
Boren, J; Martin, D; Mayersohn, M; Valdez, J, 2004
)
0.59
" Moreover, two operational defined extraction procedures commonly used in soil and sediment studies (first and second steps of BCR procedure and DTPA extraction protocol) were applied in the different mining wastes in order to study Pb and Zn mobility and likely bioavailability to Betula pendula growing on the same mining spoils, which presents lead and zinc contents in leaves over ten times background values."( Assessment of metal availability to vegetation (Betula pendula) in Pb-Zn ore concentrate residues with different features.
Carvalho, ML; Hidalgo, M; Marguí, E; Queralt, I, 2007
)
0.34
" The concentration and bioavailability of individual pollutants within particles need to be characterised to ascertain the risks to ecological receptors."( Deposition and solubility of airborne metals to four plant species grown at varying distances from two heavily trafficked roads in London.
Freer-Smith, PH; Hutchings, TR; Morgan, GW; Peachey, CJ; Sinnett, D; Wilkinson, M,
)
0.13
" Significantly higher bioavailability of inorganic ions was observed for samples collected from the area of the WNP."( Simultaneous determination of inorganic and organic ions in plant parts of Betula pendula from two different types of ecosystems (Wielkopolski National Park and Chemical Plant in Luboń, Poland).
Frankowski, M, 2016
)
0.43
" It has a wide spectrum of pharmacological activities, including being lung protective; however, its bioavailability is low."( Pharmacokinetics and Tissue Disposition of Nanosystem-Entrapped Betulin After Endotracheal Administration to Rats.
Casals, E; Karlina, MV; Kosman, VM; Makarov, VG; Pozharitskaya, ON; Rosenholm, JM; Shikov, AN, 2017
)
0.46
" Another advantage besides increased bioavailability and anticancer activity is the reduced overall systemic toxicity in most of the cases, when triterpenoids are delivered with any of the carriers."( Delivery Systems for Birch-bark Triterpenoids and their Derivatives in Anticancer Research.
Mierina, I; Turks, M; Vilskersts, R, 2020
)
0.56
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" The metabolic details of GM on MSTG-A, MSTG-B and Gualtherin were clarified in this study, providing data support and basis for clinical development and bioavailability improvement."( Biotransformation and metabolism of three methyl salicylate glycosides by gut microbiota in vitro.
Chai, K; Deng, Q; Dong, Y; He, Y; Li, X; Lv, F; Ren, X; Shan, D; She, G; Song, R; Wang, X; Zhao, Y; Zheng, Y; Zhong, X, 2023
)
1.17

Dosage Studied

The effectiveness of the topically applied product depends on the release of the drug from such a dosage form. The present study was proposed to investigate the in vitro release of methyl salicylate from the typical ointment bases and several commercial products.

ExcerptRelevanceReference
" And, since the effectiveness of the topically applied product depends on the release of the drug from such a dosage form, the present study was proposed to investigate the in vitro release of methyl salicylate from the typical ointment bases and several commercial products."( In vitro release studies of methyl salicylate from the ointment bases and the commercial dermatological products.
Barbar, A; Plakogiannis, FM; Raouf, M, 1990
)
0.76
" A study was conducted on interference with complexing anions of Fe(III), cations that react with fluoride ions and with common ingredients of dosage forms and dental preparations."( Spectrophotometric determination of fluoride in dosage forms and dental preparations.
Florean, E; Mirel, S; Oprean, R; Roman, L; Săndulescu, R; Suciu, P, 1996
)
0.29
"The total amount of salicylate recovered in the urine during two dosing intervals (24 hours) on each study day, relative to the applied dose, was used to calculate the bioavailability of each product."( Serum concentrations of salicylic acid following topically applied salicylate derivatives.
Bartle, WR; Bowles, SK; Lee, SN; Morra, P; Reeves, RA; Walker, SE, 1996
)
0.29
" The nature of this topical dosage product led the investigators to expect less than complete absorption of methyl salicylate."( Plasma salicylate from methyl salicylate cream compared to oil of wintergreen.
Casavant, MJ; Hadley, CM; Kelley, MT; Walson, PD; Wolowich, WR, 2003
)
0.84
" Dosage formulation must be considered when predicting toxicity."( Plasma salicylate from methyl salicylate cream compared to oil of wintergreen.
Casavant, MJ; Hadley, CM; Kelley, MT; Walson, PD; Wolowich, WR, 2003
)
0.63
"In the one stage experiment, no significant difference of the incidence of mice lung tumors was observed between different dosage groups of water extracts and organic extracts."( [The model of mouse lung tumor short-term induction test for assaying the carcinogencity induced by extracts of birch wood dust].
Dong, Q; He, P; Wu, D, 2002
)
0.31
" Timing and dosing of allergen(s) are of major importance."( Intervention during pregnancy and allergic disease in the offspring.
Hauser, B; Keymolen, K; Salvatore, S; Vandenplas, Y, 2005
)
0.33
" Values for birch (30 patients) showed that 1,000 STU corresponded to 77 IR, for grass (29 patients) 1,000 STU matched 78 IR and for house dust mite (30 patients) 1,000 STU matched 27 IR based on dose-response relationships."( Comparison of the biological activity of the most common sublingual allergen solutions made by two European manufacturers.
Lehmacher, W; Mösges, R; Pasch, N; Schlierenkämper, U, 2006
)
0.33
" This study investigated the clinical efficacy, safety and dose-response relationship of SLIT in children suffering from rhinoconjunctivitis with/without asthma."( Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children.
Jacobsen, L; Koivikko, A; Ljørring, C; Savolainen, J; Valovirta, E, 2006
)
0.33
"The doses of each allergen in the pair had an additive effect resulting in a shift of the dose-response curve to higher CD63 percentages and higher CD-sens."( Simultaneous exposure of several allergens has an additive effect on multisensitized basophils.
Johansson, SG; Lundberg, M; Nopp, A; Oman, H, 2006
)
0.33
" The effects of chemical type, dosage and temperature were of interest."( Coagulation of wood extractives in chemical pulp bleaching filtrate by cationic polyelectrolytes.
Leiviskä, T; Rämö, J, 2008
)
0.35
" High dosages of allergen were more effective while mode of dosing up did not seem to matter."( CD-sens: a biological measure of immunological changes stimulated by ASIT.
Cardell, LO; Johansson, SG; Nopp, A; Oman, H, 2009
)
0.35
" Recipient rats were either treated with cyclosporine A at a low dosage (Low-dose CsA=LDCsA) or received LDCsA in combination with BPE (2×1ml/day)."( Inhibition of corneal inflammation following keratoplasty by birch leaf extract.
Bredow, L; Gründemann, C; Huber, R; Kern, Y; Reinhard, T; Schwartzkopff, J; Wacker, K, 2012
)
0.38
" The enzyme dosage could be decreased to 4 FPU/g without a major effect in terms of the hydrolysis performance."( A novel alkaline oxidation pretreatment for spruce, birch and sugar cane bagasse.
Hakola, M; Kallioinen, A; Leskelä, M; Repo, T; Riekkola, T; Siika-aho, M; von Weymarn, N, 2013
)
0.39
"The purpose of the study was to examine effects of pre-treatment with a Toll-like receptor 7 (TLR7) agonist (AZD8848) in allergic rhinitis and to evaluate clinical effects of two dosing regimens."( Biological effects and clinical efficacy of a topical Toll-like receptor 7 agonist in seasonal allergic rhinitis: a parallel group controlled phase IIa study.
Ahlström-Emanuelsson, C; Alenäs, M; Almqvist, G; Andersson, M; Cervin, A; Dolata, J; Greiff, L; Lindgren, S; Mårtensson, A; Widegren, H; Young, B, 2015
)
0.42
" For this primary endpoint, a significant linear dose-response curve was observed: the higher the dose, the better the improvement observed."( A randomized DBPC trial to determine the optimal effective and safe dose of a SLIT-birch pollen extract for the treatment of allergic rhinitis: results of a phase II study.
Boot, JD; Diamant, Z; Klimek, L; Kuna, P; Opstelten, DJ; Panzner, P; Pfaar, O; van Ree, R; van Twuijver, E, 2016
)
0.43
"A multicentre trial evaluated the dose-response and tolerability of SB."( A randomized DBPC trial to determine the optimal effective and safe dose of a SLIT-birch pollen extract for the treatment of allergic rhinitis: results of a phase II study.
Boot, JD; Diamant, Z; Klimek, L; Kuna, P; Opstelten, DJ; Panzner, P; Pfaar, O; van Ree, R; van Twuijver, E, 2016
)
0.43
" Following a review of all of the available literature, the most appropriate data sets for dose-response modeling were reported by Gulati et al."( A critical review of the literature to conduct a toxicity assessment for oral exposure to methyl salicylate.
Franzen, A; Gentry, R; Greene, T; Rogers, S, 2017
)
0.68
" The consideration of both ozone-induced stomatal closure and stomatal sluggishness improved the model performance to estimate stomatal conductance and to explain the dose-response relationship on ozone-induced decline of photosynthesis of white birch."( Ozone-induced stomatal sluggishness changes stomatal parameters of Jarvis-type model in white birch and deciduous oak.
Carrari, E; Hoshika, Y; Koike, T; Paoletti, E; Watanabe, M, 2018
)
0.48
"59% in broad bean on the seventh day post application with a dosage of 600."( Efficacy of binary combinations between methyl salicylate and carvacrol against thrips Anaphothrips obscurus: laboratory and field trials.
Liu, JH; Lu, XP; Ma, ZQ; Weng, H; Zhang, X, 2020
)
0.83
" Relatively minor, immunostimulatory effects were seen following repeated subcutaneous dosing (once every 2 weeks for 13 weeks) as reversible increased white cell count (notably neutrophils), increased globulin level (resulting in decreased albumin/globulin [A/G] ratio) and increased fibrinogen, as well as minor dose site reaction in the form of inflammatory cell infiltrate."( Safety Evaluation of PQ Birch Allergy Immunotherapy to Support Product Development.
Baldrick, P; Heath, MD; Hutchings, JW; Skinner, MA, 2019
)
0.51
" We developed a system for in vitro dosing of whole pollen grains at the Air-Liquid Interface (ALI) and studied their effect on the immortalized human bronchial epithelial cell line BEAS-2B."( Dosing intact birch pollen grains at the air-liquid interface (ALI) to the immortalized human bronchial epithelial cell line BEAS-2B.
Buters, J; Candeias, J; Schmidt-Weber, CB, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (6 Items)

ItemProcessFrequency
Non food productscore-ingredient4
Open Beauty Factscore-ingredient4
en:open-beauty-factscore-ingredient2
Chapsticks and lip balmscore-ingredient1
en:Non food productscore-ingredient1
Ungüentocore-ingredient1

Roles (3)

RoleDescription
flavouring agentA food additive that is used to added improve the taste or odour of a food.
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
insect attractantA chemical that attracts insects.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
benzoate esterEsters of benzoic acid or substituted benzoic acids.
salicylatesAny salt or ester arising from reaction of the carboxy group of salicylic acid, or any ester resulting from the condensation of the phenolic hydroxy group of salicylic acid with an organic acid.
methyl esterAny carboxylic ester resulting from the formal condensation of a carboxy group with methanol.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (5)

PathwayProteinsCompounds
volatile benzenoid biosynthesis I (ester formation)119
phenylpropanoid volatiles glycoconjugation (tomato)17
methylsalicylate biosynthesis14
methylsalicylate degradation17
superpathway of methylsalicylate metabolism311

Protein Targets (20)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency63.46740.007215.758889.3584AID1224835
RAR-related orphan receptor gammaMus musculus (house mouse)Potency9.70830.006038.004119,952.5996AID1159521
GLI family zinc finger 3Homo sapiens (human)Potency17.53660.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency46.91220.000221.22318,912.5098AID1259243; AID1259381; AID743035
thyroid stimulating hormone receptorHomo sapiens (human)Potency3.98110.001318.074339.8107AID926; AID938
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency68.72910.000657.913322,387.1992AID1259377
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency22.54920.001022.650876.6163AID1224838; AID1224839; AID1224893
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency7.56240.000214.376460.0339AID720691
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency27.48260.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency24.85910.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency22.07710.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency17.26770.005428.02631,258.9301AID1346982; AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency23.71010.000229.305416,493.5996AID743079
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency21.93400.001024.504861.6448AID743215
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency0.00250.023723.228263.5986AID588543
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency68.72910.001723.839378.1014AID743083
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency35.31190.057821.109761.2679AID1159526; AID1159528
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency54.59350.000323.4451159.6830AID743065
histone deacetylase 9 isoform 3Homo sapiens (human)Potency38.64920.037617.082361.1927AID1259364
lamin isoform A-delta10Homo sapiens (human)Potency0.79430.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (33)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID26793Partition coefficient (logP)1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Quantitative structure-inhibitory activity relationships of phenols and fatty acids for Bacillus subtilis spore germination.
AID1090481Antifungal activity against Colletotrichum camelliae assessed as inhibition of mycelial growth at 2000 ug/mL measured after 5 days of cultivation2006Journal of agricultural and food chemistry, May-31, Volume: 54, Issue:11
Antifungal activities of major tea leaf volatile constituents toward Colletorichum camelliae Massea.
AID1090485Antifungal activity against Colletotrichum camelliae assessed as inhibition of mycelial growth at 100 ug/mL measured after 5 days of cultivation2006Journal of agricultural and food chemistry, May-31, Volume: 54, Issue:11
Antifungal activities of major tea leaf volatile constituents toward Colletorichum camelliae Massea.
AID40936Inhibition of Bacillus subtilis PCI219 spore germination, expressed as log 1/I501982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Quantitative structure-inhibitory activity relationships of phenols and fatty acids for Bacillus subtilis spore germination.
AID639952Inhibition of TNF-alpha-induced NF-kappaB activation in human HCT116 cells at 1 mM after 6 hrs by luciferase reporter gene assay2012European journal of medicinal chemistry, Feb, Volume: 48Structure-activity relationship of salicylic acid derivatives on inhibition of TNF-α dependent NFκB activity: Implication on anti-inflammatory effect of N-(5-chlorosalicyloyl)phenethylamine against experimental colitis.
AID444511Metabolic stability in 80% human plasma assessed as half life at pH 7.4 by RP-HPLC2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
Isosorbide-based aspirin prodrugs: integration of nitric oxide releasing groups.
AID607792Antileishmanial activity against Leishmania amazonensis MHOM/IFLA/BR/67/PH8 promastigotes after 72 hrs by cell counting using Neubauer chamber2011Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14
Design, synthesis and antileishmanial in vitro activity of new series of chalcones-like compounds: a molecular hybridization approach.
AID25611Dissociation constant (pKa)1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Quantitative structure-inhibitory activity relationships of phenols and fatty acids for Bacillus subtilis spore germination.
AID607793Antileishmanial activity against Leishmania chagasi MCAN/BR/99/JP15 promastigotes after 72 hrs by cell counting using Neubauer chamber2011Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14
Design, synthesis and antileishmanial in vitro activity of new series of chalcones-like compounds: a molecular hybridization approach.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1090713Thrips luring activity against female New Zealand Thrips obscuratus (flower thrips) assessed as ratio of thrips in baited traps to unbaited traps during field trapping study2007Journal of agricultural and food chemistry, Jul-25, Volume: 55, Issue:15
4-pyridyl carbonyl and related compounds as thrips lures: effectiveness for onion thrips and new zealand flower thrips in field experiments.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1090482Antifungal activity against Colletotrichum camelliae assessed as inhibition of mycelial growth at 1500 ug/mL measured after 5 days of cultivation2006Journal of agricultural and food chemistry, May-31, Volume: 54, Issue:11
Antifungal activities of major tea leaf volatile constituents toward Colletorichum camelliae Massea.
AID409957Inhibition of bovine liver MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID40623Inhibitory activity on germination of Bacillus subtilis PCI219 spores was determined.1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Quantitative structure-inhibitory activity relationships of phenols and fatty acids for Bacillus subtilis spore germination.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1090712Thrips luring activity against male New Zealand Thrips obscuratus (flower thrips) assessed as ratio of thrips in baited traps to unbaited traps during field trapping study2007Journal of agricultural and food chemistry, Jul-25, Volume: 55, Issue:15
4-pyridyl carbonyl and related compounds as thrips lures: effectiveness for onion thrips and new zealand flower thrips in field experiments.
AID1090483Antifungal activity against Colletotrichum camelliae assessed as inhibition of mycelial growth at 1000 ug/mL measured after 5 days of cultivation2006Journal of agricultural and food chemistry, May-31, Volume: 54, Issue:11
Antifungal activities of major tea leaf volatile constituents toward Colletorichum camelliae Massea.
AID1113018Nematicidal activity against second-stage juveniles of Meloidogyne incognita (root-knot nematode) after 1 hr by inverted microscopic analysis2013Journal of agricultural and food chemistry, Feb-27, Volume: 61, Issue:8
Potent nematicidal activity of phthalaldehyde, salicylaldehyde, and cinnamic aldehyde against Meloidogyne incognita.
AID1113017Nematicidal activity against second-stage juveniles of Meloidogyne incognita (root-knot nematode) after 1 day by inverted microscopic analysis2013Journal of agricultural and food chemistry, Feb-27, Volume: 61, Issue:8
Potent nematicidal activity of phthalaldehyde, salicylaldehyde, and cinnamic aldehyde against Meloidogyne incognita.
AID1090480Antifungal activity against Colletotrichum camelliae assessed as inhibition of mycelial growth measured after 5 days of cultivation2006Journal of agricultural and food chemistry, May-31, Volume: 54, Issue:11
Antifungal activities of major tea leaf volatile constituents toward Colletorichum camelliae Massea.
AID1090484Antifungal activity against Colletotrichum camelliae assessed as inhibition of mycelial growth at 500 ug/mL measured after 5 days of cultivation2006Journal of agricultural and food chemistry, May-31, Volume: 54, Issue:11
Antifungal activities of major tea leaf volatile constituents toward Colletorichum camelliae Massea.
AID26261Partition coefficient (logD7.2)1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Quantitative structure-inhibitory activity relationships of phenols and fatty acids for Bacillus subtilis spore germination.
AID1090711Thrips luring activity against female Thrips tabaci (onion thrips) assessed as ratio of thrips in baited traps to unbaited traps during field trapping study2007Journal of agricultural and food chemistry, Jul-25, Volume: 55, Issue:15
4-pyridyl carbonyl and related compounds as thrips lures: effectiveness for onion thrips and new zealand flower thrips in field experiments.
AID1112517Toxicity to Musca domestica (house fly) applied to pronotum assessed as compound level per fly causing insect mortality measured after 24 hr2012Pest management science, Aug, Volume: 68, Issue:8
Quantitative structure-activity relationships of monoterpenoid binding activities to the housefly GABA receptor.
AID409959Inhibition of bovine liver MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1112518Displacement of [3H]TBOB binding to GABA receptor in Musca domestica (house fly) heads homogenates assessed as [3H]TBOB binding at 500 uM incubated for 90 min by scintillation counting method2012Pest management science, Aug, Volume: 68, Issue:8
Quantitative structure-activity relationships of monoterpenoid binding activities to the housefly GABA receptor.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1346567Mouse TRPA1 (Transient Receptor Potential channels)2004Neuron, Mar-25, Volume: 41, Issue:6
Noxious cold ion channel TRPA1 is activated by pungent compounds and bradykinin.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,400)

TimeframeStudies, This Drug (%)All Drugs %
pre-199079 (3.29)18.7374
1990's52 (2.17)18.2507
2000's797 (33.21)29.6817
2010's1094 (45.58)24.3611
2020's378 (15.75)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 83.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index83.56 (24.57)
Research Supply Index7.89 (2.92)
Research Growth Index5.76 (4.65)
Search Engine Demand Index164.64 (26.88)
Search Engine Supply Index2.19 (0.95)

This Compound (83.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials134 (5.31%)5.53%
Reviews63 (2.50%)6.00%
Case Studies62 (2.46%)4.05%
Observational5 (0.20%)0.25%
Other2,261 (89.54%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (12)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Cognitive Benefits of Interactive Mental and Physical Exercise for Older Adults at Risk for or With Mild Cognitive Impairment (MCI) [NCT02237560]111 participants (Actual)Interventional2014-09-30Completed
Clinical Efficacy and Safety of Compound Methyl Salicylate Liniment in the Treatment of Acute and Chronic Soft Tissue Pain:a Multicenter, Randomized, Positive Controlled Clinical Trial [NCT03362216]216 participants (Actual)Interventional2009-04-07Completed
Which Cold Application is More Effective in Patients With Lateral Epicondylitis? [NCT04536948]54 participants (Actual)Interventional2016-03-01Completed
Impact of Combined Non-surgical and Surgical Periodontal Treatment in Patients With Type 2 Diabetes Mellitus [NCT02874963]160 participants (Anticipated)Interventional2015-11-30Recruiting
Iron Metabolism in Dragon Boat Athletes - An Analysis of Changes in Blood Count Parameters Under Sport-specific Stress [NCT01431118]40 participants (Anticipated)Interventional2011-04-30Completed
Monitoring and Managing Newly Healed Chronic Leg and Foot Ulcer Skin Temperature: A Cooling Intervention (MUSTCOOL) to Prevent Ulcer Recurrence [NCT02626156]Phase 2140 participants (Actual)Interventional2015-06-01Completed
Determining the Right Acupuncture for Good Recovery Over Neuropsychiatric Trauma (DRAGON) [NCT05516862]75 participants (Anticipated)Interventional2022-10-01Recruiting
Preventing Venous Leg Ulcers With Cryotherapy: A Randomized Clinical Trial [NCT01509599]Phase 1/Phase 2197 participants (Actual)Interventional2011-08-31Completed
Inhalation of Vapor With Medication (Diclofenac Sodium, Menthol, Methyl Salicylate and N-Acetyl Cysteine) Reduces Oxygen Need and Hospital Stay in COVID-19 Patients - A Case Control Study [NCT04900129]Phase 143 participants (Actual)Interventional2020-12-01Completed
A Randomised, Double Blind, Cross Over Clinical Study in Healthy Human Volunteers to Assess the Efficacy and Safety of Three Different Topical Analgesics (DCF100, TIB200 And SPR300) Versus in a Model of UV-Induced Inflammatory Pain [NCT02666846]Phase 160 participants (Actual)Interventional2015-03-31Completed
Quantitative Analysis of Different Acupuncture Needle Manipulation to Treat Chronic Shoulder Pain [NCT03197207]60 participants (Actual)Interventional2016-06-03Completed
Safety and Efficacy of Compound Methyl Salicylate Liniment for Topical Pain: a Multicenter Real-World Study in China [NCT05489939]3,600 participants (Actual)Observational2014-05-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT02626156 (10) [back to overview]Change in METS Minutes Engaging in Physical Activity Measured With The International Physical Activity Questionnaire
NCT02626156 (10) [back to overview]Differences in Step Counts
NCT02626156 (10) [back to overview]Knowledge Questionnaire of Study Instructions
NCT02626156 (10) [back to overview]Number of Participants With Ulcer Recurrence
NCT02626156 (10) [back to overview]Time Spent in Minutes Engaging in Physical Activities
NCT02626156 (10) [back to overview]Change in Mean Scores on Quality of Life Measured With the VEINES QOL/Sym Questionnaire
NCT02626156 (10) [back to overview]Change in Pain (Worst Pain, Least Pain, Pain Now)
NCT02626156 (10) [back to overview]Changes in Severity and Intensity Pain Scores Measured With the Brief Pain Inventory
NCT02626156 (10) [back to overview]Number of Participants Indicating 'Yes' or 'Easy' on Study Instructions, Thermometer Use, Completing Logs, Performing Treatment, Helpfulness
NCT02626156 (10) [back to overview]Participant Adherence to the Study Protocol
NCT02666846 (8) [back to overview]Adverse Events (AEs)
NCT02666846 (8) [back to overview]Area Under the Plasma Concentration Versus Time Curve
NCT02666846 (8) [back to overview]Heat Pain Tolerance Test (HPTT) Measured the Point at Which the Heat Became Painful - Degrees Centigrade -
NCT02666846 (8) [back to overview]Intensity of the UVB-induced Erythema (Determined by Assessment of Skin Blood Flow by Laser Doppler Imaging [Flux Units])
NCT02666846 (8) [back to overview]Number of Recorded Abnormal Clinical Assessments
NCT02666846 (8) [back to overview]Peak Plasma Concentration (Cmax)
NCT02666846 (8) [back to overview]Physical Exams to Ensure Safety and Well Being of the Subjects
NCT02666846 (8) [back to overview]To Determine Vital Signs and Electrocardiograms (ECGs) That Were Abnormal to Ensure Safety and Well Being of the Subjects

Change in METS Minutes Engaging in Physical Activity Measured With The International Physical Activity Questionnaire

Change in metabolic equivalent of task (METS) min per week for physical activity per The International Physical Activity Questionnaire reported for 4 groups from baseline to 6 months end of study. Scoring HIGH indicate physical activity levels equate to ~1hour of activity per day or more at least moderate intensity level or engage in vigorous intensity activity on at least 3 days achieving a minimum total physical activity of at least 1500 MET min a week or 7 or more days of any combination of walking, moderate intensity or vigorous intensity activities achieving a minimum total physical activity of at least 3000 MET min a week. MODERATE suggests engagement equivalent to 30 min of at least moderate intensity activity on most days; engage in 3 or more days of vigorous intensity activity and/or walking of at least 30 min per day or 5 or more days of moderate intensity activity and/or walking of at least 30 minutes per day. LOW level means that neither MODERATE or HIGH levels are met. (NCT02626156)
Timeframe: Through study completion at 6 months from baseline

Interventionminutes (Mean)
Cooling Gel Pack - Venous Leg Ulcer73
Cooling Cotton Pack - Venous Leg Ulcer799
Cooling Gel Pack - Diabetic Foot Ulcer1921
Cooling Cotton Pack - Diabetic Foot Ulcer225

[back to top]

Differences in Step Counts

Differences in step counts reported via accelerometer data, from baseline to post treatment at 6 months end of intervention for the 4 groups. (NCT02626156)
Timeframe: Through study completion at 6 months from baseline

InterventionSteps (Mean)
Cooling Gel Pack - Venous Leg Ulcer17295
Cooling Cotton Pack - Venous Leg Ulcer14234
Cooling Gel Pack - Diabetic Foot Ulcer13232
Cotton Cooling Pack - Diabetic Foot Ulcer15479

[back to top]

Knowledge Questionnaire of Study Instructions

"Participants were administered a 12-item (yes/no) questionnaire (test) during instruction at the start of the study, provided by the research personnel to determine comprehension of the protocol and to reinforce study procedures. Score of 12 or 100% was given for all items scoring correctly (1 point per item). Any items for which no was answered, remediation was conducted by study personnel at the time the questionnaire was conducted. Means scores are reported per VLU and DFU cooling pack intervention and VLU and DFU cotton cooling pack control." (NCT02626156)
Timeframe: Baseline after participant enrollment

Interventionscore on a scale (Mean)
Cooling Gel Pack - Venous Leg Ulcer11.7
Cooling Cotton Pack - Venus Leg Ulcer11.9
Cooling Gel Pack - Diabetic Foot Ulcer11.8
Cotton Gel Pack - Diabetic Foot Ulcer11.9

[back to top]

Number of Participants With Ulcer Recurrence

Number of recurrent ulcers that develop during the 6 month study period for in participants for 4 groups of patients with previously healed venous leg ulcers receiving the cooling gel pack and cooling cotton pack and those with previously healed diabetic foot ulcers receiving the cooling gel pack or cooling cotton pack. (NCT02626156)
Timeframe: Through study completion at 6 months from baseline

Interventionparticipants (Number)
Cooling Gel Pack - Venous Leg Ulcer6
Cooling Cotton Pack - Venous Leg Ulcer3
Cooling Gel Pack - Diabetic Foot Ulcer11
Cotton Cooling Pack - Diabetic Foot Ulcer5

[back to top]

Time Spent in Minutes Engaging in Physical Activities

Mean time spent in minutes engaging in physical activities, reported via accelerometer data, from baseline to post treatment at 6 months end of intervention for the 4 groups. (NCT02626156)
Timeframe: Through study completion at 6 months from baseline

InterventionMinutes (Mean)
Cooling Gel Pack - Venous Leg Ulcer1420
Cooling Cotton Pack - Venous Leg Ulcer2523
Cooling Gel Pack - Diabetic Foot Ulcer135
Cotton Cooling Pack - Diabetic Foot Ulcer157

[back to top]

Change in Mean Scores on Quality of Life Measured With the VEINES QOL/Sym Questionnaire

The Venous Insufficiency Epidemiological and Economic Study-Quality of life/Symptoms (VEINES QOL/Sym) Questionnaire was used to evaluate quality of life. A sum score is provided as an overall quality of life score for both the QOL and Sym portions of the questionnaire. This instrument was used only for the VLU groups because it is a disease-specific measure. Of the 26 items in the questionnaire, 25 items are combined to create a summary score (VEINES-QOL). One item which asks about the time of day the leg problem is most intense, question 2, provides only descriptive information and is not scored. A subset (symptoms score) of ten of these items, questions 1a to 1i and 7, is used to create a symptom score (VEINES-Sym). For both the VEINES-QOL and VEINES-Sym scores, high values indicate better outcomes. VEINES-QOL scores can be compared only to other members of the same sample. Each set of VEINES-QOL scores will have a mean T-score = 50. (NCT02626156)
Timeframe: Through study completion at 6 months from baseline

,
Interventiont-scores (Mean)
Quality of lifeSymptoms
Cooling Cotton Pack-4.8-4.3
Cooling Gel Pack13.824.2

[back to top]

Change in Pain (Worst Pain, Least Pain, Pain Now)

Pain was measured with a visual analog scale and reported numerically (0 to 10 with 10 being the most severe pain) at baseline and at 6 months end of study (NCT02626156)
Timeframe: Through study completion at 6 months from baseline

,,,
Interventionscore on a scale (Mean)
Worst painLeast painPain now
Cooling Cotton Pack - Diabetic Foot Ulcer-1.00-0.1
Cooling Cotton Pack - Venous Leg Ulcer0.400.14
Cooling Gel Pack - Diabetic Foot Ulcer0-0.10.1
Cooling Gel Pack - Venous Leg Ulcer0.850.30.4

[back to top]

Changes in Severity and Intensity Pain Scores Measured With the Brief Pain Inventory

The Brief Pain Inventory (BPI) scale is reported as an average score. BPI rapidly assesses the severity of pain and its impact on functioning for intensity and Pain Intensity and Pain Interference. Pain Intensity is measured in four categories: worst, least, on average, and currently, while Pain Interference is measured in 7 categories: mood, work, general activity, walking, relationships, enjoyment of life, and sleep. The patient rates each of these on a scale from 0-10, 10 being excruciating pain intensity and a complete interference in their life. Subscores are determined by averaging over the 4 intensity items for the severity subscore and over the 7 interference items for the interference subscore; possible total scores range from 0 to 10. Higher scores indicate worse intensity and severity. (NCT02626156)
Timeframe: Through study completion at 6 months from baseline

,,,
Interventionscore on a scale (Mean)
SeverityInterference
Cooling Cotton Pack - Venous Leg Ulcer-0.2-0.5
Cooling Gel Pack - Diabetic Foot Ulcer0-0.1
Cooling Gel Pack - Venous Leg Ulcer-0.5-0.4
Cotton Cooling Pack - Diabetic Foot Ulcer0.40.1

[back to top]

Number of Participants Indicating 'Yes' or 'Easy' on Study Instructions, Thermometer Use, Completing Logs, Performing Treatment, Helpfulness

"Patients satisfaction was measured by study personnel a during end of study phone survey with the following questions asked as follows (Yes/No): Were study instructions adequate, was thermometer easy to use, found cooling helpful, would cool skin area if it was proven that cooling prevented reulceration; (Easy/Not Easy): completing logs, performing the cooling treatment. Data are for (Yes/No) as number of participants who reported yes or if (Easy/Not Easy) the number of participants who reported easy." (NCT02626156)
Timeframe: Survey conducted at end of the 6-month study period.

,,,
Interventioncount of participants (Number)
Study Instructions Adequate - YesUsing Thermometer Easy - YesCompleting Logs - EasyPerforming Cooling -Treatment - EasyCooling Helpful - YesWould Cool if Found to Prevent Re-Ulceration - Yes
Cooling Cotton Pack - Venous Leg Ulcer343233312133
Cooling Gel Pack - Diabetic Foot Ulcer262727262124
Cooling Gel Pack - Venous Leg Ulcer363636353134
Cotton Cooling Pack - Diabetic Foot Ulcer252525241825

[back to top]

Participant Adherence to the Study Protocol

Using study data logs, appropriate use of the thermometer and cooling pack was measured by the number of participants who adhered to the protocol for taking the temperature of the skin over the healed venous leg or diabetic foot ulcer. Adherence was defined as: the number of participants who were at least 80% adherent to taking their temperatures with the infrared thermometer each morning and the number of participants who were at least 80% adherent to performing the intervention every other day = 3 times times per week during the 6-month study period. (NCT02626156)
Timeframe: Daily measures starting at baseline for temperature and every other day cooling application during the 6-month study period.

InterventionParticipants (Count of Participants)
TemperatureCooling
Adherence10682

[back to top]

Adverse Events (AEs)

Local and systemic Adverse Events (AEs). (NCT02666846)
Timeframe: Estimated study duration for each subject will be approximately 6 weeks

InterventionEvents (Number)
Cohort 1: TIB200 Gel 10%5
Cohort 1: Nurofen Gel 10%5
Cohort 1: Nurofen Tablets1
Cohort 1: TIB200 Placebo Gel1
Cohort 2: DCF100 Gel 2%1
Cohort 2: DCF100 Gel 4%1
Cohort 2: Voltaren Gel 2%0
Cohort 2: Voltarol Oral Tablet2
Cohort 2: DCF100 Placebo Gel0
Cohort 3: SPR300 Gel (15%:7%)3
Cohort 3: SPR300 Placebo Gel1

[back to top]

Area Under the Plasma Concentration Versus Time Curve

Area under the concentration vs. time curve from time zero to 6 hours (AUC0-6h) (up to 6 subjects per cohort only) laser Doppler imaging [flux units], up to 6 subjects per cohort) (NCT02666846)
Timeframe: 15 minutes before and 1, 2, 4 and 6 hours post administration

Interventionh*ng/ml (Mean)
Cohort 1: TIB200 Gel 10%47.7
Cohort 1: Nurofen Gel 10%19.9
Cohort 1: Nurofen Tablets90000
Cohort 2: DCF100 Gel 2%0
Cohort 2: DCF100 Gel 4%0
Cohort 2: Voltaren Gel 2%0
Cohort 2: Voltarol Oral Tablet1030
Cohort 3: SPR300 Gel (15%:7%)0
Cohort 3: SPR300 Placebo Gel0

[back to top]

Heat Pain Tolerance Test (HPTT) Measured the Point at Which the Heat Became Painful - Degrees Centigrade -

To assess the pharmacodynamic effect by Heat Pain Tolerance Test (HPTT) which measured the point at which the heat became painful (degrees centigrade) of three topical analgesics, DCF100, TIB200, and SPR300 versus topical placebo and active topical reference products in a model of UV-induced inflammatory pain. (NCT02666846)
Timeframe: 15 minutes before to 6 hours post administration

InterventionDegrees Centigrade (Mean)
Cohort 1: TIB200 Gel 10%0.3635
Cohort 1: Nurofen Gel 10%0.7358
Cohort 1: Nurofen Tablets0.0887
Cohort 1: TIB200 Placebo Gel-0.1983
Cohort 2: DCF100 Gel 2%0.6679
Cohort 2: DCF100 Gel 4%0.8722
Cohort 2: Voltaren Gel 2%0.7978
Cohort 2: Voltarol Oral Tablet0.6835
Cohort 2: DCF100 Placebo Gel0.1688
Cohort 3: SPR300 Gel (15%:7%)0.3934
Cohort 3: SPR300 Placebo Gel-0.0123

[back to top]

Intensity of the UVB-induced Erythema (Determined by Assessment of Skin Blood Flow by Laser Doppler Imaging [Flux Units])

Intensity of the Ultra Violet B radiation (UVB)-induced erythema (determined by assessment of skin blood flow by laser Doppler imaging [flux units], up to 8 subjects per cohort) - Change from baseline (NCT02666846)
Timeframe: 15 minutes before to 6 hours post administration

InterventionLaser doppler imaging (Flux Units) (Least Squares Mean)
Cohort 1: TIB200 Gel 10%-313.3879
Cohort 1: Nurofen Gel 10%-171.5589
Cohort 1: Nurofen Tablets-262.0693
Cohort 1: TIB200 Placebo Gel-95.3974
Cohort 2: DCF100 Gel 2%-228.3016
Cohort 2: DCF100 Gel 4%-278.1918
Cohort 2: Voltaren Gel 2%-198.1408
Cohort 2: Voltarol Oral Tablet-198.1408
Cohort 2: DCF100 Placebo Gel-45.376
Cohort 3: SPR300 Gel (15%:7%)12.2265
Cohort 3: SPR300 Placebo Gel67.3931

[back to top]

Number of Recorded Abnormal Clinical Assessments

"Laboratory assessments - standard clinical trial assessments for clinical chemistry and haematology~Listing of individual laboratory measurements by subjects and evaluation of each laboratory parameter" (NCT02666846)
Timeframe: Estimated study duration for each subject will be approximately 6 weeks

InterventionAssessments (Number)
Cohort 1: TIB200 Gel 10%0
Cohort 1: Nurofen Gel 10%0
Cohort 1: Nurofen Tablets0
Cohort 1: TIB200 Placebo Gel0
Cohort 2: DCF100 Gel 2%0
Cohort 2: DCF100 Gel 4%0
Cohort 2: Voltaren Gel 2%0
Cohort 2: Voltarol Oral Tablet0
Cohort 2: DCF100 Placebo Gel0
Cohort 3: SPR300 Gel (15%:7%)0
Cohort 3: SPR300 Placebo Gel0

[back to top]

Peak Plasma Concentration (Cmax)

Maximum observed plasma concentration (Cmax), time corresponding to occurrence of Cmax (tmax) (up to 6 subjects per cohort only) laser Doppler imaging [flux units], up to 6 subjects per cohort) (NCT02666846)
Timeframe: 15 minutes before and 1, 2, 4 and 6 hours post administration

Interventionng/ml (Mean)
Cohort 1: TIB200 Gel 10%11.5
Cohort 1: Nurofen Gel 10%5.15
Cohort 1: Nurofen Tablets29900
Cohort 2: DCF100 Gel 2%0
Cohort 2: DCF100 Gel 4%0
Cohort 2: Voltaren Gel 2%0
Cohort 2: Voltarol Oral Tablet772
Cohort 3: SPR300 Gel (15%:7%)0
Cohort 3: SPR300 Placebo Gel0

[back to top]

Physical Exams to Ensure Safety and Well Being of the Subjects

Physical examinations - including assessments of the application site. examination. (NCT02666846)
Timeframe: Estimated study duration for each subject will be approximately 6 weeks

InterventionAbnormalities (Number)
Cohort 1: TIB200 Gel 10%0
Cohort 1: Nurofen Gel 10%0
Cohort 1: Nurofen Tablets0
Cohort 1: TIB200 Placebo Gel0
Cohort 2: DCF100 Gel 2%0
Cohort 2: DCF100 Gel 4%0
Cohort 2: Voltaren Gel 2%0
Cohort 2: Voltarol Oral Tablet0
Cohort 2: DCF100 Placebo Gel0
Cohort 3: SPR300 Gel (15%:7%)0
Cohort 3: SPR300 Placebo Gel0

[back to top]

To Determine Vital Signs and Electrocardiograms (ECGs) That Were Abnormal to Ensure Safety and Well Being of the Subjects

To determine Vital Signs and Electrocardiograms (ECGs) that were abnormal to ensure safety and well being of the subjects (NCT02666846)
Timeframe: Estimated study duration for each subject will be approximately 6 weeks

InterventionAbnormal readings (Number)
Cohort 1: TIB200 Gel 10%0
Cohort 1: Nurofen Gel 10%0
Cohort 1: Nurofen Tablets0
Cohort 1: TIB200 Placebo Gel0
Cohort 2: DCF100 Gel 2%0
Cohort 2: DCF100 Gel 4%0
Cohort 2: Voltaren Gel 2%0
Cohort 2: Voltarol Oral Tablet0
Cohort 2: DCF100 Placebo Gel0
Cohort 3: SPR300 Gel (15%:7%)0
Cohort 3: SPR300 Placebo Gel0

[back to top]